Clinical & Translational Learnings of BNT-221, a Neoantigen-Specific Adoptive T-Cell Therapy & Next Steps for Future Product Iterations
Time: 12:30 pm
day: Conference Day One - Track B - AM
Details:
- An insight into NEO-STIM and its applications: our process to prime, activate and expand neoantigen specific T-cells
- An overview of clinical safety and efficacy results of BNT221 and deep characterization of the generated drug products and peripheral samples
- An outlook of what is next including process improvements and product enhancements
